Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tozorakimab in Moderate to Severe COPD with Chronic Bronchitis
NCT04631016Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of tozorakimab in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB), sponsored by AstraZeneca. Primary endpoint: Pre-bronchodilator Forced Expiratory Volume in 1 Second at 12 weeks. Started Dec 2020; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT04631016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631016.